TCT-76

Percutaneous Ventricular Restoration (PVR) therapy using the Parachute® Device in Patients with Ischemic Dilated Heart Failure: PARACHUTE III, European Post Market Trial, Primary Endpoint Results

Martyn Thomas1, Christoph A. Nienaber2, Huseyn Ince1, Andreaes Erglis2, Vladas Yakvevicius2, Ulrich Schafer2, Rui C. Ferreira1, Corrado Tamburino2
1Department of Cardiology, St. Thomas’ Hospital, London, UK, London, United Kingdom, 2University of ROSTOCK, Rostock, Germany, 3University of Rostock, Rostock, Germany, 4Pauls Stradins Clinical University Hospital, Riga, Latvia, 5Clinic Center of Serbia, Belgrade, Serbia, 6Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany, Hamburg, Germany, 7Hospital Santa Maria, Lisbon, Lisbon, 8University of Catania, Catania, Italy

Background: Left ventricular (LV) remodeling after anterior wall myocardial infarction (AWMI) leads to increased LV volumes, myocardial stress, and ultimately heart failure (HF). Treatment options are limited for these high-risk HF patients.

Methods: Aims: The primary objective is to continue to assess the long term safety of the CardiOKinetics Parachute Implant System in the partitioning of the left ventricle in patients with heart failure due to ischemic heart disease. One hundred patients with NYHA class III-IV HF secondary to AWMI, with akinesic or dyskinesic wall motion abnormality, and LV ejection fraction < 40%, were enrolled in Europe. The primary endpoint was site-reported procedural and device related MACE in real world use of the Parachute Implant through 5 years of clinical follow-up. Secondary endpoints included changes in LVEFsvi, LVEDVi, 6MWT, and the number of and time to the combined cardiovascular mortality and morbidity that includes all cause death, hospitalization for heart failure, myocardial infarction, and stroke, whichever is earlier, within 6, and 12 months from the date of implantation of the study device.

Results: As of the last data cut in early 2014, a pooled analysis which included 77 of the 100 PARACHUTE III patients, showed significant reductions (p < 0.05) in LVESVi and LVEDVi at 1 year as well as a significant improvement in the 6MWT data. One-year follow-up of the full cohort of 100 patients will be available for the TCT conference in September 2014.

Conclusions: The analysis of the post market data confirms the safety and longer term efficacy of the Parachute device in treating HF.

TCT-77

Midterm results of a Novel Interatrial Shunt Therapy for Heart Failure and Preserved Ejection Fraction

Finn Gustafsson1, Filip Malek2, Petr Neuzil3, Lars Sondergaard4, Tony Walton1
1Rigshospitalet, Copenhagen, Denmark, 2Na Homolce Hospital, Prague, CZ, 3Clinic Center of Serbia, Belgrade, Serbia, 4Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany, Hamburg, Germany, 5Hospital Santa Maria, Lisbon, Lisbon, 6University of Catania, Catania, Italy

Background: Approximately 50% of patients presenting with clinical features of heart failure have a preserved ejection fraction (“HFPEF”). The fundamental pathophysiological basis for the HFPEF phenotype is impaired diastolic reserve, with elevated resting, or rapid increase in LVVEDP, LAP and pulmonary artery pressures during low level physical activity. We report the midterm results of a novel device intended to lower left atrial pressure by creating a small permanent atrial septal shunt. Objective: Evaluation of safety and potential benefits of the intra atrial shunt device (IASD™) System in patients with symptomatic heart failure with preserved or mildly reduced ejection fraction, despite appropriate medical management.

Methods: Eleven patients were enrolled under an approved protocol in a prospective multicenter feasibility study. Key inclusion criteria were: EF > 45%; PCWP at rest ≥ 15 or exercise ≥ 25mm Hg ≥ 1 hospitalization for heart failure within prior 12 months, or persistent NYHA Class III/IV for at least 3 months.

Results: Mean age, and EF, were 75 Y, and 57 %, respectively. Most patients had multiple comorbidities. The IASD Device was successfully implanted in each patient within 30 days, and both were closed. At 30-90 days, PCWP was reduced (4 mmHg, P < 0.001) with no change in CVP, and at 6 months clinical symptoms had improved (See Table). One year follow-up data will be presented.

Conclusions: This initial data demonstrates that the shunt device can be safely implanted and that midterm clinical improvement can be obtained in patients with heart failure and preserved or mildly reduced ejection fraction.

TCT-78

Predictors of Survival in Patients Undergoing Trans-Catheter Aortic Valve Closure for Significant Left Ventricular Assist Device Associated Aortic Insufficiency

Elizabeth Retzer1, Corey E. Tabit1, J Raider Estrada1, Jonathan D. Paul1, Sandeep Nathan1, Janet Friest1, Roberto M. Lang1, Amran P. Shah1
1University of Chicago, Chicago, IL, 2University of Chicago Medical Center, Chicago, IL

Background: Left ventricular assist devices (LVADs) have been shown to increase survival and quality of life in patients with end-stage congestive heart failure. However, severe aortic insufficiency (AI) can develop in up to 50% of patients with LVADs at 12 months resulting in significant morbidity and mortality. Trans-catheter treatment of LVAD associated AI has emerged as a potential alternative to surgical treatment, but long term clinical benefits are yet to be determined.

Methods: We conducted a retrospective analysis of all patients undergoing transcatheter aortic valve closure using an Amplatzer Multi-Fenestrated Septal Occluder (“Cribiform” device (AGA Medical, Plymouth, Minnesota) at our institution between September 2011 and September 2013 to assess potential clinical and procedural factors associated with survival. Unpaired student’s t-tests were used to compare baseline patient demographics and procedural characteristics, as well as patient outcomes immediately post procedure and at 6 months. A p-value of < 0.05 was considered statistically significant.

Results: A total of 8 patients (75% male, median age 59 years) were included in this analysis. Technical success of the procedure including total cessation of AI without evidence of coronary compromise was accomplished in 100% of patients with a 6 month survival rate of 38% (3/8). Predictors of survival include the absence of significant co-morbidities such as chronic renal insufficiency, smaller occlusion device placement, and the absence of right heart failure (Table 1).

Table 1. Predictors of Survival

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>6 months</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>NYHA III/IV (%) (n=10)</td>
<td>80/20</td>
<td>20/0</td>
<td>NA</td>
</tr>
<tr>
<td>6 MWD (m (n=9)</td>
<td>342 ± 139</td>
<td>369 ± 92</td>
<td>0.096</td>
</tr>
<tr>
<td>NT-Pro-BNP (pmol/L (n=9)</td>
<td>193 ± 153</td>
<td>262 ± 210</td>
<td>0.370</td>
</tr>
<tr>
<td>MLWHF score (n=10)</td>
<td>54 ± 18</td>
<td>31 ± 17</td>
<td>0.009</td>
</tr>
</tbody>
</table>

Conclusions: Trans-catheter aortic valve closure successfully treats late severe AI in LVAD patients, however, the presence or development of right heart failure portends a worse prognosis. Further studies are needed to investigate the potential right ventricular failure in patients undergoing trans-catheter aortic valve closure.